The 2026 Q2 earnings season is winding down, with Apple (NASDAQ: AAPL), EMCOR Group (NYSE: EME), and Johnson & Johnson (NYSE: JNJ) among the standout performers posting record-breaking results.
Apple delivered its strongest June-quarter performance in company history, reporting quarterly revenue of $109.4 billion, representing a 16% increase year-over-year.
Adjusted earnings per share came in at $2.02, reflecting an even more impressive 29% increase compared to the same period last year.
The tech giant posted double-digit revenue growth across iPhone, Mac, and Services segments, with similar gains recorded across every major geographic region.
Apple’s installed base of active devices reached an all-time high across its major product categories, while its overall gross margin received a boost from tariff refunds.
iPhone remained the company’s largest revenue driver, generating $54.3 billion in quarterly sales and growing 21.6% year-over-year, continuing its dominance as the flagship product line.
The Services category has grown into a major revenue contributor, posting quarterly sales of $30.7 billion, which represents a 12% year-over-year increase.
Apple also reported record operating cash flow for its June-quarter period, reinforcing the company’s reputation for exceptional cash generation that has long supported its premium stock valuation.
EMCOR Group posted revenues of $5.2 billion, marking a quarterly record and reflecting nearly 20% year-over-year growth, while adjusted EPS of $9.06 represented a second-quarter-specific record, up 35% from the prior year period.
Remaining performance obligations reached an all-time high of $17.1 billion, surging 44% year-over-year and signaling continued strong demand across EMCOR’s construction and services operations.
EMCOR capped off its results with increased sales and earnings guidance for the remainder of the fiscal year, reinforcing confidence in the company’s ongoing growth trajectory.
Johnson & Johnson shares have delivered a gain of nearly 30% in 2026, quietly outperforming many of its large-cap peers while also showing strong outperformance relative to the S&P 500 over the past month.
The healthcare giant reported quarterly sales of $25.3 billion, a new company record, reflecting solid year-over-year revenue growth of 6.6% as its diversified business continued to perform.
Johnson & Johnson also raised both its fiscal year sales and adjusted EPS guidance, with the company now on track to surpass $100 billion in annual revenue for the first time in its history.
The overall Q2 earnings landscape remains one of strength, with these three companies exemplifying the positive momentum that has characterized the reporting season despite mixed reactions across the broader market.
